Published November 15, 2012
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker. [ read more ]
Utah Business Social
CEO of the Year 2014!Mar 27, 2014Utah’s business landscape is rich with professionals who have led the Beehive State’s economy to ...